Medical Knowledge Cockpit adenocarcinoma

 

• egf signaling pathway
  species not specified one gene

  ---

• role of egf receptor transactivation by gpcrs in cardiac hypertrophy
  species not specified one gene

  ---

• keratinocyte differentiation
  species not specified one gene

  ---

• cbl mediated ligand-induced downregulation of egf receptors pathway
  species not specified one gene

  ---

• map kinase inactivation of smrt corepressor
  species not specified one gene

  ---

• agrin in postsynaptic differentiation
  species not specified one gene

  ---

 

BRAF

This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This proteinplays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation,and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterizedby heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also beenassociated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroidcarcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located onchromosome X, has been identified for this gene. (provided by RefSeq, Jul 2008)

This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases

This proteinplays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation,and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterizedby heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also beenassociated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroidcarcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located onchromosome X, has been identified for this gene. (provided by RefSeq, Jul 2008)

 

BRAF

Somatic tumors

melanoma, colorectal, papillary thyroid, borderline ovarian, NSCLC, cholangiocarcinoma, pilocytic astrocytoma, Spitzoid tumour, pancreas acinar carcinoma, melanocytic nevus, prostate, gastric

Tumor types germline

Cancer Syndrom

Translocation partner

AKAP9, KIAA1549, CEP88, LSM14A, SND1, FCHSD1, SLC45A3, FAM131B, RNF130, CLCN6, MKRN1, GNAI1, AGTRAP

Name

v-raf murine sarcoma viral oncogene homolog B1

Chromosome banding

7q34

Cancer molecular gen.

Dom

Mutation type

Mis, T, O

Other syndrome disease

Cardio-facio-cutaneous syndrome

 

EGFR

• Quantitative methods for the analysis of protein phosphorylation in drug development
• Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials
• Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis
• Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients
• Mechanisms of cutaneous toxicities to EGFR inhibitors

• EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR)
• The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells
• ADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation
• Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities
• A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation
• Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation
• Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates
• cbl-b inhibits epidermal growth factor receptor signaling

 

BRAF

• Recent advances in the understanding of Langerhans cell histiocytosis
• BRAF mutations in hairy-cell leukemia
• Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-Raf
• BRAF V600E is a determinant of sensitivity to proteasome inhibitors

• Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

ERBB2

• Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer
• ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas
• Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription
• c-erbB-2 gene product directly associates with beta-catenin and plakoglobin

RAD54L

• Human and mouse homologs of the Saccharomyces cerevisiae RAD54 DNA repair gene: evidence for functional conservation

MSR1

• Lipid accumulation and dendritic cell dysfunction in cancer